CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
接受免疫检查点抑制剂、CAR-T 细胞和双特异性 T 细胞衔接器治疗患者的感染事件：注册研究综述
英文原题：Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies.
查看英文原题
Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在 ICIs、CAR-T 细胞和 BiTEs 的注册研究和临床试验中，报告了多种感染。
研究思路结论见上方概要
背景
免疫治疗（免疫检查点抑制剂[ICIs]、CAR-T[CAR-T]细胞、双特异性T细胞衔接器[BiTEs]）已深刻改变了多种癌症的治疗。然而，这些治疗对感染发生风险的影响尚未完全明确。
方法
我们回顾了目前获批的ICIs、CAR-T 细胞和BiTEs的所有注册研究，以收集所有报告的感染。针对每种药物，我们生成了一份报告，其中包含至少10%入组患者发生的感染。
结果
接受 ICIs 治疗的患者中最常报告感染涉及呼吸道，包括鼻咽炎、上呼吸道感染和肺炎，以及泌尿道。接受 CAR-T 细胞治疗的患者常报告未特指的感染和侵染、细菌感染和病毒感染的发生率。在接受 BiTEs 治疗的患者中，鼻咽炎、肺炎和器械相关感染是最常报告的情况。
展开英文摘要原文
BACKGROUND
Immunological treatments (immune checkpoint inhibitors [ICIs], chimeric antigen receptor T [CAR-T] cells, bispecific T-cell engagers [BiTEs]) have deeply changed the treatment of several cancers. However, the impact of these treatments on the risk of developing infections has not been completely ascertained yet.
METHODS
We reviewed all the registration studies of currently approved ICIs, CAR-T cells, and BiTEs to collect all the reported infections. For each drug, we have generated a report with the infections occurring in at least 10% of the patients enrolled.
RESULTS
The most frequently reported infections involving patients treated with ICIs involved the respiratory tract, including nasopharyngitis, upper respiratory tract infections, and pneumonia and the urinary tract. Those treated with CAR-T cells frequently reported the incidence of unspecified infections and infestations, bacterial infections, and viral infections. In patients treated with BiTEs, nasopharyngitis, pneumonia, and device-related infections were the most frequently reported conditions.
CONCLUSIONS
A wide range of infections are reported in registration studies and clinical trials of ICIs, CAR-T cells, and BiTEs.
论文信息
- 作者
- Lombardi A、Saydere A、Ungaro R、Bozzi G、Viero G、Bandera A、Gori A、Mondelli MU
- 单位
- Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy. Electronic address: andrea.lombardi@unimi.it.Italy
- 文献类型
- 综述
- 期刊
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022 Jul
- 原文标识
- PubMed 35429642 · DOI 10.1016/j.ijid.2022.04.022